Roche Holding AG (RHHBY.PK), Tuesday announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity Elecsys Troponin T test for diagnosing heart attacks.
The results showed that the test was able to detect even the slightest elevations in troponin levels, a critical biomarker for heart attack, enabling patients to receive life-saving care at the earliest.
It also identified whether patients had acute myocardial infarction or not with huge precision, helping clinicians to provide faster and reliable diagnosis in emergencies.
Currently, Roche's stock is moving up 3.33 percent, to $40.91 on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.